cap-1

CAP-1 is an inhibitor of HIV-1 capsid formation.

Cap-dependent endonuclease-IN-1 is a highly potent, orally active cap-dependent endonuclease inhibitor with antiviral activity for studying influenza virus infection.

NLRP3-IN-51 (Compound 3q) is an effective activator of the cholinergic anti-inflammatory pathway (CAP). This compound demonstrates potential for treating gouty arthritis as it inhibits the production of IL-1β in THP-1 cells induced by monosodium urate (MSU). Furthermore, NLRP3-IN-51 suppresses the phosphorylation of NF-κBp65 triggered by MSU without impacting the self-cleavage and activation of NLRP3, pro-caspase 1, or the second messenger caspase-1. Therefore, the initial stage of NLRP3 inhibition by NLRP3-IN-51 occurs through the activation of CAP.

Suberoylanilide hydroxamic acid (SAHA) is a class I and class II histone deacetylase (HDAC) inhibitor that binds directly to the catalytic site of the enzyme thereby blocking substrate access. [1] coumarin-Suberoylanilide hydroxamic acid (c-SAHA) is a SAHA derivative where the anilino cap group is replaced by 7-amino-4-methylcoumarin to produce a fluorescent probe that competitively binds HDAC. [2] The fluorescence excitation and emission maxima of free c-SAHA is 325 and 400 nm

1,2-Dipalmitoyl-sn-glycero-3-PE-N-(cap biotin) is a biotinylated phospholipid. It has been used in PEGylated polyamidoamine-dendrimer-conjugated supported lipid bilayers (SLB) to isolate circulating tumor cells and tumor cell microembolis from patient-derived blood by antibody-coated microfluidics. [1] It has also been used as a component of SLBs to detect protein-ligand binding with ortho-conjugated Texas Red DHPE. [2] In addition, 1,2-dipalmitoyl-sn-glycero-3-PE-N-(cap biotin) has been used in SLBs partitioned into nanowells to create DNA curtains, which can be used as a high-throughput tool for detection of protein-DNA interactions at the single molecule level.[3]

Methyl brevifolincarboxylate (Brevifolincarboxylic acid methyl ester) is a potent influenza virus PB2 cap-binding inhibitor, exhibiting inhibitory activity against influenza virus A Puerto Rico 8 34 (H1N1) and A Aichi 2 68 (H3N2) with IC50s of 27.16 μM and 33.41 μM, respectively, and possessing anti-oxidant activity[1][2].

2',3'-O-Isopropylideneguanosine is an alkylated guanosine building block.1,2It has been used in the synthesis of ordered honeycomb microporous films and mRNA cap analogs. 1.Gao, Y.-F., Huang, Y.-J., Xu, S.-Y., et al.Ordered honeycomb microporous films from self-assembly of alkylated guanosine derivativesLangmuir27(6)2958-2964(2011) 2.Kore, A.R., Shanmugasundaram, M., and Vlassov, A.V.Synthesis and application of a new 2',3'-isopropylidene guanosine substituted cap analogBioorg. Med. Chem. Lett.18(17)4828-4832(2008)

7-Methylguanosine 5'-diphosphate (7-Methyl-GDP) sodium, a cap analog, is utilized in the synthesis of mRNA cap analogues[1].

Cap-dependent endonuclease-IN-26, a potent inhibitor of cap-dependent endonuclease (CEN) with an IC50 of 286 nM, exhibits significant antiviral activity against a broad spectrum of influenza A and B strains [1].

Cap-dependent endonuclease-IN-9 is a potent cap-dependent endonuclease (CEN) inhibitor with notable efficacy against the influenza virus, minimal cytotoxicity, enhanced in vivo pharmacokinetics, and robust pharmacodynamics. It effectively suppresses the RNA polymerase activity of Influenza A virus[1].

N7-Methylguanosine-5'-triphosphate-5'-adenosine (m7GpppA) diammonium, a dinucleotide cap analog, facilitates in vitro RNA transcription [1].

Cap-dependent Endonuclease-IN-12 (EXP-35) is a potent inhibitor of Cap-dependent endonuclease, demonstrating low cytotoxicity. This compound exhibits inhibitory effects on H1N1 [1].

Cap-dependent endonuclease-IN-22 is a potent inhibitor of cap-dependent endonuclease (CEN) [1].

M7GpppApG is a trinucleotide mRNA 5' cap analog utilized for in vitro RNA synthesis [1].

3'Ome-m7GpppAmpG, a trinucleotide cap analogue with a locked nucleic acid (LNA) molecule, demonstrates notable translational efficiency. It serves as a promising tool in molecular biology, applicable in mRNA vaccines and transfection processes, including protein production, gene therapy, and anti-cancer immunization [1].

3'Ome-m7GpppAmpG ammonium, a trinucleotide Cap analogue with a locked nucleic acid (LNA) component, demonstrates substantial translational efficiency. It emerges as a promising tool in molecular biology, applicable in mRNA vaccines and transfection processes including protein production, gene therapy, and anti-cancer immunization [1].

M7GpppAmpG is a trinucleotide 5′ cap analog, exhibiting capping efficiencies of 90% for the produced RNAs [1].

m7GpppAmpG ammonium is a trinucleotide 5′ cap analog with capping efficiencies of 90% for RNAs obtained [1].

m7Gpppm6AmpG, a trinucleotide mRNA 5' cap analog, facilitates RNA synthesis in vitro [1].

M7Gpppm6AmpG ammonium, a trinucleotide mRNA 5' cap analog, facilitates in vitro RNA synthesis [1].

M7GpppGpG, a trinucleotide cap analogue and oligonucleotide, protects against premature degradation by 5′-exonucleases and facilitates pre-mRNA splicing, mRNA transport, and protein biosynthesis initiation by recruiting essential proteins [1].

m7GpppGmpG, a trinucleotide 5′ cap analog, exhibits capping efficiencies of 86% for the RNAs obtained [1].

M7GpppGmpG ammonium, a trinucleotide 5′ cap analog, exhibits an 86% capping efficiency for the produced RNAs [1].

m7GpppUmpG, an oligonucleotide and a trinucleotide cap analogue of M 7 GpppNpG, serves as a chemical tool for the production of RNA with either cap 0 or cap 1 structures [1].